Light & Recovery
Circadian Daylight and Melanopic EDI: Why Eyes Beat UV for Sleep Timing
≥250 melanopic lux days, ≤10 evenings, dark nights—visible light, not tanning.
Circadian benefits of daylight are primarily ocular visible light via melanopsin/ipRGCs, quantified as melanopic EDI: day ≥~250, evening ≤~10, night ≤~1 (Brown et al. 2022). This is orthogonal to UVB vitamin D. Morning outdoor light is high-EV; tanning is not circadian care.
You can perfect your vitamin D protocol and still wreck your clock with dim days and bright nights. Spectrum, intensity, timing, and which organ receives the photons all matter.
This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.
What pathway times the human clock?
Light is the dominant zeitgeber. Intrinsically photosensitive retinal ganglion cells express melanopsin and project to the suprachiasmatic nucleus, aligning circadian phase.
Morning light tends to advance the clock; evening/night light delays it and can suppress melatonin—modern device lighting is a major misalignment driver (Blume review).
Vitamin D UVB chemistry peaks near ~295 nm; melanopsin sensitivity peaks in short-wavelength visible (~480 nm region)—different tools.
What are the Brown 2022 quantitative targets?
Daytime: melanopic EDI ≥ ~250 lux at the eye during the day.
Evening: ≤ ~10 lux melanopic EDI in the three hours before intended sleep.
Sleep period: as dark as practicable, ≤ ~1 lux melanopic EDI. Consensus coauthors include major chronobiology leaders—use as design targets, not malpractice law.
| Period | Melanopic EDI target | Practical cue |
|---|---|---|
| Daytime | ≥ ~250 lux | Outdoor morning bout |
| Evening (≤3 h pre-bed) | ≤ ~10 lux | Dim lamps, low screens |
| Sleep | ≤ ~1 lux | Dark room |
| UVB vitamin D | Separate pathway | Skin, not clock |
How to implement without gadgets first?
Take a 10–30+ minute outdoor morning bout with eyes receiving daylight (not face buried in a dark phone in a cave).
Brighten daytime indoor work if outdoor access is limited; dim overheads and screens at night; blackout or eye mask if needed for sleep darkness.
SAD-style 10,000 lux light boxes are visible-light tools with minimal UV when properly designed—follow device guidance, not sunbed logic.
How to dual-source UV risk messaging?
WHO UV protection advice when UV index is high remains valid for skin and eye cancer/photodamage risk. It does not cancel the need for daytime visible light.
Integrate: seek daylight for eyes; protect skin appropriately; never use erythema as a sleep therapy. Contested influencer claims that demand maximal UV for “mitochondria” should not erase either circadian consensus or dermatology risk data.
Sources: Brown et al. PLOS Biology 2022 consensus; Blume et al. light and circadian review; WHO ultraviolet radiation fact sheet.
Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Sources & citations
Frequently asked